75Se-labelled methotrexate has been used as the radiolabel in a radioimmunoassay for methotrexate and its use compared with that of 3H-methotrexate. The gamma-labelled drug has proved to be extremely reliable and easier to use than 3H-methotrexate. Results obtained with it compare well with those obtained with tritiated drug. There are practical advantages in using a gamma emitter, and it is suggested that the modified radioimmunoassay is invaluable for routine monitoring of methotrexate in patients undergoing chemotherapy with the drug.
References
1.
AherneG. W.PiallE. M.MarksV. (1977). Development and application of a radioimmunoassay for methotrexate. British Journal of Cancer, 36, 608–617.
2.
AherneG. W.PiallE.MarksV.MouldG. M.WhiteW. F. (1978). Prolonged and increased methotrexate concentrations using probenecid in man. British Medical Journal, 1, 1097–1099.
3.
AlbanoJ.EkinsR. P. (1970). In: In vitro Procedures with Radioisotopes in Medicine, pp. 491–513. IEAE, Vienna.
4.
BohuonC.DupreyF.BoudeneC. (1974). Radioimmunoassay of methotrexate in biological fluids. Clinica Chimica Acta, 57, 263–267.
5.
Freeman-NarrodM.GerstleyB. J.EngstromP. F.BornsteinR. F. (1975). Comparison of serum concentrations of methotrexate after various routes of administration. Cancer, 36, 1619–1624.
6.
FreiE.JaffeN.TattersallM. H. N.PitmanS.ParkerL. (1975). New approaches to cancer chemotherapy with methotrexate. New England Journal of Medicine, 292, 846–851.
7.
HendelJ.SarekL. J.HindbergE. F. (1976). Rapid radioimmunoassay for methotrexate in biological fluids. Clinical Chemistry, 22, 813–816.
8.
LevineL.PowersE. (1974). Radioimmnoassay for methotrexate. Research Communications in Chemical Pharmacology9, 543–554.
9.
LoefflerL. J.BlumM. R.NelsonM. A. (1976). A radioimmunoassay for methotrexate and its comparison with spectrofluorimetric procedures. Cancer Research, 36, 3306–3311.
10.
RasoV.SchreiberR. (1975). A rapid and specific radioimmunoassay for methotrexate. Cancer Research, 35, 1407–1410.
11.
ShapiroW. R.YoungD. F.MehtaB. M. (1975). Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. New England Journal of Medicine, 293, 161–166.
12.
StollerR. G.HandeK. R.JacobsS. A.RosenbergS. A.ChabnerB. A. (1977). Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine, 297, 630–634.
